In the absence of head-to-head trials, the findings help validate the applicability of phase 3 results to routine care. The study was published as a preprint and has not yet been peer reviewed.
The drug combination, which received accelerated approval from the FDA for patients aged 6 years and older, is the only BRAF/MEK inhibitor okayed for use in pediatric patients.
While the "Moonshot" aims at the future, a "groundshot" initiative could address the issues facing cancer patients right now by making better use of services that are already available.